

Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A lactose-free pharmaceutical composition which comprises an optically pure enantiomer of (S) fluoxetine, or a pharmaceutically acceptable salt thereof, and at least one non-lactose pharmaceutically acceptable excipient.
2. (Currently Amended) A solid pharmaceutical composition which comprises an optically pure enantiomer of (S) fluoxetine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein said excipient is not lactose.
3. (Original) The composition of claim 1, wherein said non-lactose pharmaceutically acceptable excipient is a binder, a filler, or a mixture thereof.
4. (Original) The composition of claim 2, wherein said pharmaceutically acceptable excipient is a binder, a filler, or a mixture thereof.
5. (Original) The composition of claim 3 or 4 wherein said binder is a starch.
6. (Original) The composition of claim 3 or 4 wherein said binder is a cellulose.
7. (Original) The composition of claim 5 wherein said starch is selected from the group consisting of corn starch, potato starch, pre-gelatinized starch and a mixture thereof.
8. (Original) The composition of claim 6 wherein said cellulose is selected from the group consisting of ethyl cellulose, cellulose acetate, carboxymethyl

cellulose calcium, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, microcrystalline cellulose and a mixture thereof.

9. (Original) The composition of claim 3 or 4, which further comprises a lubricant, disintegrant, or mixtures thereof.

10. (Canceled)

11. (Canceled)

12. (Original) The composition of claim 1 or 2, wherein said pharmaceutical composition is substantially free of all mono- or di-saccharides.

*12 cont*

13. (Currently Amended) A chemically stable compressed tablet free of lactose which comprises an optically pure enantiomer of (S) fluoxetine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, wherein said tablet does not dissolve in less than three minutes when subjected to the DISSOLUTION TEST.

14. (Currently Amended) A chemically stable compressed tablet free of lactose which comprises about 1% to about 50% by weight of an optically pure enantiomer (S) fluoxetine or a pharmaceutically acceptable salt thereof, and about 99% to about 50% by weight of at least one pharmaceutically acceptable excipient, wherein said tablet does not dissolve in less than three minutes when subjected to the DISSOLUTION TEST.

15. (Original) The compressed tablet of claims 13 or 14 wherein said tablet does not contain a disintegrant.

16. (Previously Amended) The compressed tablet of claim 13 or 14 wherein said tablet dissolves and disperse uniformly in more than five minutes when subjected to the DISSOLUTION TEST.

17. (Original) The compressed tablet of claim 13 or 14, wherein said fluoxetine is present in an amount from about 1 mg to about 200 mg.

18. (Original) The compressed tablet of claim 17, wherein said fluoxetine is present in an amount of about 2 mg to about 100 mg.

19. (Canceled)

20. (Canceled)

21. (Currently Amended) A stable, solid compressed tablet consisting essentially of ~~racemic fluoxetine, an optically pure enantiomer (S) fluoxetine~~ or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose and pre-gelatinized starch.

22. (Previously Amended) The compressed tablet of claim 13 or 14, wherein said compressed tablet is sterile, anhydrous and non-hygroscopic.

23. (Currently Amended) An anhydrous solid pharmaceutical composition which comprises ~~an optically pure enantiomer of (S) fluoxetine or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.~~

24. (Original) The composition of claim 23 wherein said composition does not contain lactose.

25. (Original) The composition of claim 23 or 24 wherein said composition is a compressed tablet.

26. (Canceled)

27. (Canceled)

28. (Original) The composition of claim 23 or 24 wherein said composition is non-hygroscopic.

29. (Original) The composition or tablet of claim 1, 13, 14, 21, 23, or 24 wherein said pharmaceutically acceptable salt is a hydrochloride salt.

30. (Currently Amended) A stable pharmaceutical unit dosage form which comprises an optically pure enantiomer of (S) fluoxetine, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients wherein said dosage form is not a capsule or gel cap and does not dissolve in less than three minutes when subjected to the DISSOLUTION TEST.

31. (Canceled)

32. (Canceled)

33. (Currently Amended) A solid compressed tablet substantially free of lactose which comprises an optically pure enantiomer of (S) fluoxetine, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient which is not lactose.

34. (Currently Amended) A disintegrating tablet substantially free of lactose which comprises an optically pure enantiomer of (S) fluoxetine, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient which is not lactose.

35. (Original) A method of treating depression in a mammal which comprises the oral administration of a therapeutically effective amount of a composition or tablet of claim 1, 2, 13, 14, 21, 23, 24, 30, 33 or 34 to said mammal.

36. (Currently Amended) An anhydrous or non-hygroscopic pharmaceutical composition consisting essentially of an optically pure enantiomer of

*82 cont.*

(S) fluoxetine, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, wherein the composition is substantially free of unbound water.

37. (Previously Added) The compressed tablet of claim 21 wherein said tablet dissolves in more than five minutes when subjected to the DISSOLUTION TEST.